

APA062Mu01 100µg

Active Interleukin 16 (IL16)

Organism Species: *Mus musculus (Mouse)*

Instruction manual

FOR RESEARCH USE ONLY

NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

13th Edition (Revised in Aug, 2023)

[PROPERTIES]

Source: Prokaryotic expression.

Host: *E. coli*

Residues: Thr1203~Ser1322

Tags: N-terminal His-tag

Purity: >90%

Endotoxin Level: <1.0EU per 1µg (determined by the LAL method).

Buffer Formulation: PBS, pH7.4, containing 0.01% SKL, 5%Trehalose .

Original Concentration: 200µg/mL

Applications: Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 6.4

Predicted Molecular Mass: 16.1kDa

Accurate Molecular Mass: 18kDa as determined by SDS-PAGE reducing conditions.

[USAGE]

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCE]

```
TDSAASAS AASDISVESK EATVCTVTLE KTSAGLGPSL EGGKGS LHGD
KPLTINRIFK GTEQGEMVQP GDEILQLAGT AVQGLTRFEA WNVIKALPDG
PVTIVIRRTS LQCKQTTASA
DS
```

[ACTIVITY]

Interleukin 16 (IL-16), formerly known as lymphocyte chemoattractant factor or LCF, is a pro-inflammatory cytokine that is chemotactic for CD4+ T lymphocytes, monocytes, and eosinophils. In addition to inducing chemotaxis, IL-16 can upregulate IL-2 receptor and HLA-DR4 expression, inhibit T cell receptor (TcR)/CD3-dependent activation, and promote repression of HIV-1 transcription. Besides, Interleukin 1 Alpha (IL1a) has been identified as an interactor of IL-16, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant mouse IL-16 and recombinant dog IL1a. Briefly, IL-16 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μ l were then transferred to IL1a-coated microtiter wells and incubated for 1h at 37°C. Wells were washed with PBST and incubated for 1h with anti-IL-16 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37 °C, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50 μ L stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant mouse IL-16 and recombinant dog IL1a was shown in Figure 1, the EC50 for this effect is 1.9 ug/mL.




Figure 1. The binding activity of recombinant mouse IL-16 and recombinant dog IL1a

[IDENTIFICATION]




Figure 2. SDS-PAGE

Sample: Active recombinant IL16, Mouse

[IMPORTANT NOTE]

The kit is designed for research use only, we will not be responsible for any issue if the kit was used in clinical diagnostic or any other procedures.